Table 3.
Multivariable Analysis of Overall Survival
| Variable | Hazard Ratio | 95% CI |
|---|---|---|
| Age | ||
| 18–59 | 1 | |
| 60–69 | 1.17 | (0.97–1.41) |
| ≥70 | 1.39 | (1.14–1.70) |
| Sex | ||
| Men | 1 | |
| Women | 0.83 | (0.71–0.96) |
| WHO performance score | ||
| 0 | 1 | |
| 1 | 1.44 | (1.22–1.71) |
| ≥2 | 1.85 | (1.41–2.44) |
| Unknown | 1.75 | (1.36–2.25) |
| Number of metastatic organs | ||
| 1 | 1 | |
| 2 | 1.30 | (1.08–1.56) |
| ≥3 | 2.02 | (1.70–2.41) |
| PD-L1 | ||
| 0% | 1 | |
| 1%–49% | 0.63 | (0.51–0.76) |
| 50%–89% | 0.53 | (0.44–0.64) |
| ≥90% | 0.38 | (0.30–0.49) |
| Year | ||
| 2019 | - | |
| 2020 | ||
| KRAS | ||
| KRAS non-G12C | 1 | |
| KRAS G12C | 0.95 | (0.82–1.10) |
CI, confidence interval; PD-L1, programmed death-ligand 1.